COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases | Zendy

Sorin Drăghici | Zendy; TuanMinh Nguyen | Zendy; Larry A. Sonna | Zendy; Cordelia Ziraldo | Zendy; Radu Vanciu | Zendy; Raef Fadel | Zendy; Austin Morrison | Zendy; Rachel M. Kenney | Zendy; George Alangaden | Zendy; Mayur Ramesh | Zendy; Gil Mor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases

Author(s) -

Sorin Drăghici,

TuanMinh Nguyen,

Larry A. Sonna,

Cordelia Ziraldo,

Radu Vanciu,

Raef Fadel,

Austin Morrison,

Rachel M. Kenney,

George Alangaden,

Mayur Ramesh,

Gil Mor

Publication year - 2021

Publication title -

bioinformatics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.599

H-Index - 390

eISSN - 1367-4811

pISSN - 1367-4803

DOI - 10.1093/bioinformatics/btab163

Subject(s) - methylprednisolone , cytokine storm , dexamethasone , medicine , covid-19 , inflammation , ards , bioinformatics , lung , disease , biology , infectious disease (medical specialty)

COVID-19 has several distinct clinical phases: a viral replication phase, an inflammatory phase and in some patients, a hyper-inflammatory phase. High mortality is associated with patients developing cytokine storm syndrome. Treatment of hyper-inflammation in these patients using existing approved therapies with proven safety profiles could address the immediate need to reduce mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research